Published in J Clin Oncol on February 01, 1998
Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer Lett (2011) 1.71
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer (2004) 1.67
Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. ACS Nano (2012) 1.23
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int J Nanomedicine (2007) 1.10
Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol (2012) 1.09
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev (2014) 1.02
Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8. Pediatr Blood Cancer (2015) 0.99
Primary cardiac angiosarcoma. Sarcoma (2006) 0.98
Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine (2007) 0.97
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Metastatic Kaposi's Sarcoma with Perirectal Involvement Diagnosed with Endoscopic Ultrasound-Guided EchoBrush Cytology Sampling. Case Rep Gastroenterol (2011) 0.86
Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer (2000) 0.86
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs (2000) 0.86
Targeted therapy for Kaposi sarcoma. BioDrugs (2009) 0.86
Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. J Int AIDS Soc (2015) 0.85
Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother (2011) 0.83
A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi. AIDS Res Treat (2012) 0.81
Gastrointestinal Kaposi's sarcoma: Case report and review of the literature. World J Gastrointest Pharmacol Ther (2015) 0.80
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol (2012) 0.79
Review. Gastroenterol Hepatol (N Y) (2010) 0.79
Trends in Kaposi's Sarcoma in Miami Beach from 1987 to 2007. ISRN Oncol (2012) 0.75
Advances in the systemic treatment of cutaneous sarcomas. Semin Oncol (2012) 0.75
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma. Biologics (2009) 0.75
Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. Br J Cancer (2004) 0.75
Pulmonary Kaposi's sarcoma as the initial presentation of human immunodeficiency virus infection. IDCases (2014) 0.75
Hepatic Kaposi sarcoma: A case report and review of the literature. World J Hepatol (2017) 0.75
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med (1993) 4.88
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 3.03
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med (1996) 2.67
HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil. N Engl J Med (1989) 2.45
Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal coronary balloon angioplasty. Circulation (1999) 2.13
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol (1998) 2.12
Human cryptosporidiosis: spectrum of disease. Report of six cases and review of the literature. Arch Intern Med (1983) 2.10
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS (1998) 2.05
High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol (1996) 1.81
Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood (1991) 1.80
Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol (2000) 1.68
Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax (2009) 1.65
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis (2006) 1.64
Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immune Defic Syndr (1993) 1.64
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med (1996) 1.64
Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. Clin Infect Dis (1995) 1.51
Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav (1997) 1.51
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Extracorporeal photopheresis in Sézary syndrome. Lancet (1997) 1.44
Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.43
Usefulness of flow volume loops in emergency center and ICU settings. Chest (1997) 1.43
Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant (1999) 1.41
Cancer and HIV infection. BMJ (1991) 1.40
Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer. Cancer Invest (2000) 1.39
Multimodal therapy from stage-II breast cancer. Lancet (1978) 1.38
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr (1999) 1.35
Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol (1999) 1.34
Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG. Science (1971) 1.33
Immunological characterization of homosexual males. Cancer Res (1983) 1.29
Immunogenicity and antigenicity of lymphoid cells treated with neuraminidase. Nat New Biol (1971) 1.29
Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol (2003) 1.24
Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci U S A (1993) 1.24
Detection of Toxoplasma gondii in cerebrospinal fluid from AIDS patients by polymerase chain reaction. J Clin Microbiol (1992) 1.21
Poly-2-vinylpyridine N-oxide reverses the immunosuppressive effects of silica and carrageenan. Transplantation (1972) 1.18
Mönckeberg's sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia (1983) 1.18
Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology (2001) 1.17
AIDS exacerbates psoriasis. N Engl J Med (1985) 1.15
Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med (1996) 1.12
Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J Med Virol (2001) 1.10
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 1.10
HIV-related ocular microangiopathic syndrome and color contrast sensitivity. Invest Ophthalmol Vis Sci (1994) 1.08
Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol (1985) 1.07
Serum neopterin levels as predictor of AIDS. Klin Wochenschr (1988) 1.06
Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol (1993) 1.05
Primitive leiomyosarcoma of the breast: case report and review of the literature. Breast (2004) 1.04
Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.04
Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action. J Acquir Immune Defic Syndr (1993) 1.04
Hyperlipidemia under treatment with proteinase inhibitors. Infection (1999) 1.03
Elevated serum thymosin alpha 1 levels associated with evidence of immune dysregulation in male homosexuals with a history of infectious diseases or Kaposi's sarcoma. N Engl J Med (1983) 1.03
Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. J Infect Dis (1998) 1.03
20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol (1995) 1.02
Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. J Infect Dis (1999) 1.02
Delayed onset right-sided diaphragmatic hernia secondary to group B streptococcal infection. Pediatr Infect Dis J (1991) 1.02
Deficits in perimetric performance in patients with symptomatic human immunodeficiency virus infection or acquired immunodeficiency syndrome. Am J Ophthalmol (1995) 1.00
Retinal microvasculopathy and reduced cerebral blood flow in patients with acquired immunodeficiency syndrome. Am J Ophthalmol (1992) 1.00
[Intestinal spirochetosis in HIV infection: prevalence, isolation and morphology of spirochetes]. Dtsch Med Wochenschr (1990) 1.00
Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr (2001) 1.00
An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med (1999) 0.99
Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol (2003) 0.99
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med (2012) 0.99
Cooperative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci U S A (1993) 0.98
Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. Surgery (1971) 0.98
Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol (2008) 0.97
Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol (1987) 0.97
Cryptosporidial cholecystitis. N Engl J Med (1983) 0.97
Disseminated infection due to Mycobacterium avium-intracellulare in a homosexual man with Kaposi's sarcoma. J Infect Dis (1982) 0.96
Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer (1996) 0.96
Immunological characterizations of patients with acquired immune deficiency syndrome, acquired immune deficiency syndrome-related symptom complex, and a related life-style. Cancer Res (1984) 0.96
Pentoxifylline and wellbeing in patients with cancer. Lancet (1990) 0.95
Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res (2001) 0.95
Effect of dietary nucleotides on small intestinal repair after diarrhoea. Histological and ultrastructural changes. Gut (1994) 0.94
Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice. J Natl Cancer Inst (1971) 0.94
A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. J Virol (1995) 0.94
Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis (2005) 0.93
Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol (1997) 0.93
Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr (2001) 0.93
Does the standard vs piggyback surgical technique affect the development of early acute renal failure after orthotopic liver transplantation? Transplant Proc (2003) 0.92
Frosted branch angiitis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol (1992) 0.92
Limited value of PCR for detection of Toxoplasma gondii in blood from human immunodeficiency virus-infected patients. J Clin Microbiol (1997) 0.91
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol (2006) 0.91
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS (2001) 0.91
Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr (1994) 0.90
Impairment of colour contrast sensitivity and neuroretinal dysfunction in patients with symptomatic HIV infection or AIDS. Br J Ophthalmol (1993) 0.90
Synergistic stimulatory effects of tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type 1 and on apoptosis of HIV-1-infected host cells. Eur J Clin Invest (1996) 0.90
HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.90
Comparative effect of Mycobacterium bovis- and neuraminidase-treated tumor cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice. Cancer Res (1972) 0.90
Nonbacterial thrombotic endocarditis in a male homosexual with Kaposi's sarcoma. Arch Intern Med (1983) 0.90
Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS (1991) 0.90
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team. Antivir Ther (2000) 0.90
The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. Virology (1998) 0.89
German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res (2004) 0.89
Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy. Natl Cancer Inst Monogr (1973) 0.88
Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med (Berl) (1994) 0.88
T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol (2001) 0.88
Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J Hematol (2001) 0.88
Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. Infection (1996) 0.88
Recurrent papillary thyroid cancer: analysis of prognostic factors including the histological variant. Eur J Surg (2001) 0.88